Log In
Print
BCIQ
Print
Print this Print this
 

BeiGene-283, BGB-283

  Manage Alerts
Collapse Summary General Information
Company BeiGene Co. Ltd.
DescriptionSmall molecule BRAF inhibitor
Molecular Target BRAF
Mechanism of ActionBRAF inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat BRAF or K-Ras (KRAS)-mutation positive cancer; Treat cancer
Regulatory Designation

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today